Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 5/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL574558 | 0.86 | FDPS (0.43) | LAP3FDPS | |
| Phosphoric Acid SCHEMBL574780 | 0.86 | FDPS (0.43) | LAP3FDPS | |
| SCHEMBL533350 | 0.83 | — | — | |
| SCHEMBL30704478 | 0.78 | PGK1 (0.39) | — | |
| SCHEMBL6728630 | 0.72 | — | — | |
| SCHEMBL5144163 | 0.72 | — | — | |
| SCHEMBL6294099 | 0.72 | — | — | |
| SCHEMBL29094833 | 0.72 | CYP3A4 (0.42) | — | |
| SCHEMBL15309950 | 0.71 | TSHR (0.41) | — | |
| Phosphoric Acid SCHEMBL29250066 | 0.71 | ALDH1A1 (0.60) | LAP3FDPSMMP1MMP2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8049010-B2 | Using 4-4'-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde as raw material; cyanation to 4-4'-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-acrylonitrile; carbonylation, chain extension, hydrolysis, neutralization, decomposition, catalysis | Anhui Qingyun Pharmaceuticals & Chemical Co., Ltd. (CN) | 2011-11-01 | — | — | US | claimed |
| US-20080091014-A1 | Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates | ANHUI QUINGYUN PHARMACEUTICAL AND CHEMICAL CO., LTD. (CN) | 2008-04-17 | — | — | US | claimed |
| US-8049010-B2 | Using 4-4'-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde as raw material; cyanation to 4-4'-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-acrylonitrile; carbonylation, chain extension, hydrolysis, neutralization, decomposition, catalysis | Anhui Qingyun Pharmaceuticals & Chemical Co., Ltd. (CN) | 2011-11-01 | — | — | US | disclosed |
| US-8049010-B2 | Using 4-4'-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde as raw material; cyanation to 4-4'-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-acrylonitrile; carbonylation, chain extension, hydrolysis, neutralization, decomposition, catalysis | Anhui Qingyun Pharmaceuticals & Chemical Co., Ltd. (CN) | 2011-11-01 | — | — | US | disclosed |
| US-20080091014-A1 | Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates | ANHUI QUINGYUN PHARMACEUTICAL AND CHEMICAL CO., LTD. (CN) | 2008-04-17 | — | — | US | disclosed |
| US-20080091014-A1 | Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates | ANHUI QUINGYUN PHARMACEUTICAL AND CHEMICAL CO., LTD. (CN) | 2008-04-17 | — | — | US | disclosed |
| US-4070468-A | ANTIALLERGENS | SANDOZ, INC. (US) | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091014-A1 | Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates | KCNN4, HCN4, CACNB4 | LAP3 826/4885FDPS 192/4885MMP1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.